The submission is supported by comprehensive analytical and clinical data package, including data from the phase I/III ROSALIA study, announced on 19 September 2022 [1].

Denosumab is a humanized monoclonal antibody that is an inhibitor of the receptor activator of nuclear factor kappa-B ligand (RANKL), which works by preventing the development of osteoclasts which are cells that break down bone. It is used for the treatment of osteoporosis, treatment-induced bone loss, metastases to bone and giant cell tumour of bone [2]. The originator product is Amgen’s Prolia/Xgeva (denosumab).

A brief overview of Sandoz’s biosimilar portfolio includes SOK583A1 (aflibercept) currently in phase III and a wide range of collaborations on biosimilars covering:
1.    a commercialization agreement with Bio-Thera Solutions on a proposed biosimilar bevacizumab (BAT1706) in the US, Europe, Canada and selected other countries [3]
2.    a global commercialization agreement with Polpharma Biologics on a proposed natalizumab biosimilar [4]
3.    an agreement with EirGenix on a proposed biosimilar trastuzumab [5]
4.    a supply and commercialization partnership with Gan & Lee, a leading insulin supplier headquartered in China, to bring to market biosimilar versions of glargine, lispro and aspart insulins [6]
5.    a global partnership with Biocon in the area of immunology [7]. 

Sandoz’s denosumab biosimilar GP2411 BLA includes all the indications covered by the reference product, however, the originator product is still under patent in the US until 2025 [7].

Related articles
Organon–Henlius partnership: biosimilars for women’s health 

Theramex to market Prolia biosimilar in Europe and Australia

References
1. GaBI Online - Generics and Biosimilars Initiative. Successful trials for Sandoz and Lannett biosimilars [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2023 Mar 9]. Available from:
www.gabionline.net/biosimilars/research/successful-trials-for-sandoz-and-lannett-biosimilars
2. GaBI Online - Generics and Biosimilars Initiative. Biosimilars of denosumab [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2023 Mar 9]. Available from:
www.gabionline.net/biosimilars/general/Biosimilars-of-denosumab
3. GaBI Online - Generics and Biosimilars Initiative. FDA accepts application for bevacizumab biosimilar BAT1706 [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2023 Mar 9]. Available from:
www.gabionline.net/biosimilars/news/FDA-accepts-application-for-bevacizumab-biosimilar-BAT1706
4. GaBI Online - Generics and Biosimilars Initiative. Applications for natalizumab biosimilars accepted by FDA and EMA [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2023 Mar 9]. Available from:
www.gabionline.net/biosimilars/news/applications-for-natalizumab-biosimilars-accepted-by-fda-and-ema
5. GaBI Online - Generics and Biosimilars Initiative. Sandoz and EirGenix make deal for trastuzumab biosimilar [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2023 Mar 9]. Available from:
www.gabionline.net/pharma-news/Sandoz-and-EirGenix-make-deal-for-trastuzumab-biosimilar
6. GaBI Online - Generics and Biosimilars Initiative. Sandoz makes biological deal in China [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2023 Mar 9]. Available from: www.gabionline.net/pharma-news/Sandoz-makes-biological-deal-in-China
7. GaBI Online - Generics and Biosimilars Initiative. Biocon and Sandoz join forces for global next generation biosimilars[www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2023 Mar 9]. Available from:
www.gabionline.net/pharma-news/Biocon-and-Sandoz-join-forces-for-global-next-generation-biosimilars
8. Derbyshire M. Patent expiry dates for biologicals: 2018 update. Generics and Biosimilars Initiative Journal (GaBI Journal). 2019;8(1):24-31. doi:10.5639/gabij.2019.0801.003

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2023 Pro Pharma Communications International. All Rights Reserved.